▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2642 by analyst upside · 2026-09-27
RVMD
Revolution Medicines, Inc.
Healthcare · Market Cap $44B · P/E 0x
ANALYST PRICE TARGET
+23.9%
implied upside to consensus target
Current Price $204.97
Consensus Target $253.92
Bull Target $320.0
Bear Target $179.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
16
Hold
1
Sell
0
52-Week Low $44.05
52-Week High $224.31
YTD Return +159.4%
FUNDAMENTALS
Market Cap $44B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-8.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $44.05
52-Week High $224.31
Current Price $204.97
Bear Target $179.0
Bull Target $320.0
● Now $204.97 ● Target $253.92
TRADING DATA
Avg Volume 2.0M
YTD Return +159.4%
Analyst Count 22
Consensus Buy
Upside to Target +23.9%
Last Updated 2026-09-27

ANALYST SUMMARY

Revolution Medicines, Inc. (RVMD) is currently trading at $204.97 with a Wall Street consensus price target of $253.92, implying potential upside of 23.9% over the next 12 months. 22 analysts currently cover RVMD, with a consensus rating of Buy - 95% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $320.0, while the most cautious has a target of $179.0.

RVMD operates in the Healthcare sector with a market capitalisation of $44B. The stock is up 159.4% year-to-date and is currently trading near the upper end of its 52-week range of $44.05 – $224.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RVMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities - Reiterated
Buy → Buy 2026-09-21 Building track record
Morgan Stanley ● Initiated
Overweight 2026-09-10 Building track record
Stifel - Reiterated
Buy → Buy 2026-09-09 Building track record
Needham - Reiterated
Buy → Buy 2026-08-31 20% win rate (5 calls)
UBS - Reiterated
Buy → Buy 2026-08-28 33% win rate (6 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-28 62% win rate (8 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-08-27 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-27 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
24/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →